Skip to main content
Top
Published in: Cancer Causes & Control 1/2018

01-01-2018 | Original paper

Serum lipids and risk of obesity-related cancers in postmenopausal women

Authors: Geoffrey C. Kabat, Mimi Y. Kim, Rowan T. Chlebowski, Mara Z. Vitolins, Sylvia Wassertheil-Smoller, Thomas E. Rohan

Published in: Cancer Causes & Control | Issue 1/2018

Login to get access

Abstract

Purpose

Obesity, which is commonly accompanied by dyslipidemia, is associated with an increased risk of certain cancers. However, the association of serum lipids with specific obesity-related cancers is unclear.

Methods

We examined the association of baseline lipids (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides) with risk of developing seven obesity-related cancers in a subcohort of 24,208 participants in the Women’s Health Initiative. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for quartiles of lipids with cancers of the breast, colorectum, pancreas, endometrium, ovary, and kidney, and multiple myeloma.

Results

Total cholesterol and LDL-C showed no association with these outcomes. HDL-C was inversely associated, and triglycerides were positively associated, with several cancers. However, after adjustment for other lipids or insulin, consideration of preclinical disease, and exclusion of women taking statins, most associations were attenuated and no longer significant. Only the inverse association of HDL-C with pancreatic cancer (HR for highest vs. lowest quartile 0.52, 95% CI 0.32–0.85, p for trend 0.007) and the positive association of triglycerides with kidney cancer (HR for highest vs. lowest quartile 3.21, 95% CI 1.63–6.33, p for trend = 0.0001) remained significant. However, the inverse association of HDL-C with pancreatic cancer was no longer significant when women who lost substantial weight before diagnosis were excluded.

Conclusions

Our results suggest that when possible sources of confounding and bias are taken into account there are few robust associations of lipids with obesity-related cancers.
Literature
1.
go back to reference Renehan AG, Tyson M, Egger M, Heller R, Zwalen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRefPubMed Renehan AG, Tyson M, Egger M, Heller R, Zwalen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRefPubMed
2.
go back to reference Wang J, Yang D-L, Chen Z-Z, Gou B-F (2016) Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol 42:1–8CrossRefPubMed Wang J, Yang D-L, Chen Z-Z, Gou B-F (2016) Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol 42:1–8CrossRefPubMed
3.
go back to reference Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med 375:794–798CrossRefPubMed Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med 375:794–798CrossRefPubMed
4.
go back to reference Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and cancer risk: a systematic review and meta-analysis. Diabetes Care 35:2402–2411CrossRefPubMedPubMedCentral Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and cancer risk: a systematic review and meta-analysis. Diabetes Care 35:2402–2411CrossRefPubMedPubMedCentral
5.
go back to reference Kabat GC, Kim M, Chlebowski RT et al (2009) A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev 18:2046–2053CrossRef Kabat GC, Kim M, Chlebowski RT et al (2009) A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev 18:2046–2053CrossRef
6.
go back to reference Kabat GC, Kim MY, Peters U et al (2012) A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. Europ J Cancer Prev 2:326–332CrossRef Kabat GC, Kim MY, Peters U et al (2012) A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. Europ J Cancer Prev 2:326–332CrossRef
8.
go back to reference Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Can Res 50:23412346 Vatten LJ, Foss OP (1990) Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women. Can Res 50:23412346
9.
go back to reference Høyer AP, Englholm G (1992) Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 3:403–408CrossRefPubMed Høyer AP, Englholm G (1992) Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 3:403–408CrossRefPubMed
10.
go back to reference Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 5:501–509CrossRefPubMed Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 5:501–509CrossRefPubMed
11.
go back to reference Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, Orentreich N (1998) Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomark Prev 7:483–488 Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, Orentreich N (1998) Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomark Prev 7:483–488
12.
go back to reference Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271CrossRefPubMed Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271CrossRefPubMed
13.
go back to reference Furberg A-S, Veierød MB, Wilsgaard et al (2004) Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 96:1152–1160CrossRefPubMed Furberg A-S, Veierød MB, Wilsgaard et al (2004) Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 96:1152–1160CrossRefPubMed
14.
go back to reference Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR (2008) HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 18:671–677CrossRefPubMedPubMedCentral Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR (2008) HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 18:671–677CrossRefPubMedPubMedCentral
15.
go back to reference Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, Wallldius G, Lambe M, Wigertz A, van Hemelrijk M (2012) Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomark Prev 21:1381–1384CrossRef Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, Wallldius G, Lambe M, Wigertz A, van Hemelrijk M (2012) Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomark Prev 21:1381–1384CrossRef
16.
go back to reference His M, Zelek L, Deschasaux M et al (2014) Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol 29:119–132CrossRefPubMed His M, Zelek L, Deschasaux M et al (2014) Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol 29:119–132CrossRefPubMed
17.
go back to reference Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O (2016) Apolipoproteins, lipids, and risk of cancer. Int J Cancer 138:2648–2656CrossRefPubMed Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O (2016) Apolipoproteins, lipids, and risk of cancer. Int J Cancer 138:2648–2656CrossRefPubMed
18.
19.
go back to reference Touvier M, Fassier P, His M et al (2015) Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Brit J Nutr 114:347–357CrossRefPubMed Touvier M, Fassier P, His M et al (2015) Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Brit J Nutr 114:347–357CrossRefPubMed
20.
go back to reference Van Juijnhoven FJB, Dueno-de-Mesquita HB, Calligaro M et al (2010) Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 60:1094–1102CrossRef Van Juijnhoven FJB, Dueno-de-Mesquita HB, Calligaro M et al (2010) Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 60:1094–1102CrossRef
21.
go back to reference Ahn J, Lim U, Weinstein SJ et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomark Prev 18:2814–2821CrossRef Ahn J, Lim U, Weinstein SJ et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomark Prev 18:2814–2821CrossRef
22.
23.
go back to reference Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J et al (2010) Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171:892–902CrossRefPubMed Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J et al (2010) Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171:892–902CrossRefPubMed
24.
go back to reference Seth D, Garmo H, Wigertz A, Holmberg L, Hammar N, Jungner I et al (2012) Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int J Mol Epidemiol Genet 3:122–133PubMedPubMedCentral Seth D, Garmo H, Wigertz A, Holmberg L, Hammar N, Jungner I et al (2012) Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int J Mol Epidemiol Genet 3:122–133PubMedPubMedCentral
25.
go back to reference Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27–33CrossRefPubMed Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27–33CrossRefPubMed
27.
go back to reference Liu Y, Tang W, Wang J, Xie L, Li T, He Y, Deng Y, Peng Q, Li S, Qin X (2014) Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 25:237–249CrossRefPubMed Liu Y, Tang W, Wang J, Xie L, Li T, He Y, Deng Y, Peng Q, Li S, Qin X (2014) Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control 25:237–249CrossRefPubMed
28.
go back to reference Lytas T, Nikolopoulos G, Bonovas S (2014) Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol 20:1858–1870CrossRef Lytas T, Nikolopoulos G, Bonovas S (2014) Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol 20:1858–1870CrossRef
29.
go back to reference The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef
30.
go back to reference Langer RD, White E, Lewis CE et al (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107-S121CrossRef Langer RD, White E, Lewis CE et al (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107-S121CrossRef
31.
go back to reference McTiernan A, Kooperberg C, White E et al (2003) Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women’s Health Initiative Cohort Study. JAMA 290:1331–1336CrossRefPubMed McTiernan A, Kooperberg C, White E et al (2003) Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women’s Health Initiative Cohort Study. JAMA 290:1331–1336CrossRefPubMed
32.
go back to reference Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13(9 Suppl):S122–S128CrossRefPubMed Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13(9 Suppl):S122–S128CrossRefPubMed
33.
go back to reference Jafri H, Alsheikh-Ali AA, Karas RH (2010) Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 55:2846–2854CrossRefPubMed Jafri H, Alsheikh-Ali AA, Karas RH (2010) Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 55:2846–2854CrossRefPubMed
34.
go back to reference Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 380:581–590CrossRefPubMed Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 380:581–590CrossRefPubMed
35.
go back to reference Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098CrossRefPubMedPubMedCentral Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094–1098CrossRefPubMedPubMedCentral
Metadata
Title
Serum lipids and risk of obesity-related cancers in postmenopausal women
Authors
Geoffrey C. Kabat
Mimi Y. Kim
Rowan T. Chlebowski
Mara Z. Vitolins
Sylvia Wassertheil-Smoller
Thomas E. Rohan
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 1/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0991-y

Other articles of this Issue 1/2018

Cancer Causes & Control 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine